See below for a comprehensive list of adverse effects. <>>>/BBox[0 0 595.44 841.68]/Length 117>>stream Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Nafcillin: May decrease the serum concentration of NIFEdipine. Use of immediate-release nifedipine (oral or sublingual) is not recommended due to increased adverse effects (hypotension and reflex tachycardia). Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Other side effects include: acute myocardial infarction, muscle cramps, tremor, cough, dyspnea, hypotension, and wheezing. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. Talk with the doctor.• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).Larotrectinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products. In general, can take with or without food.Extended release: Adalat CC, Afeditab CR: Take on an empty stomach (manufacturer's labeling). Available for Android and iOS devices.We comply with the HONcode standard for trustworthy health information - Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Phenytoin: NIFEdipine may increase the serum concentration of Phenytoin. Management: Seek alternatives to the CYP3A4 substrate when possible. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. We comply with the HONcode standard for trustworthy health information - endobj Pharmacological studies have shown that verapamil has the most negative chrono- tropic and inotropic effects of the three, with nifedipine producing the most vasodilation and having the potential for causing reflex tachycardia. Management: Consider avoiding this combination. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated. nied by reflex tachycardia. Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. VinCRIStine (Liposomal): NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal). Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. endstream In- travenous saline, activated charcoal, calcium gluconate, and dopamine infusions accelerated the …